Xelix SR1.5 mg

Xelix SR is indicated for the following uses:

Established / FDA-approved uses

• Hypertension: Xelix SR is indicated for the management of hypertension, either used alone or in combination with other antihypertensive agents.
• Edema of congestive heart failure: Xelix SR is indicated for the treatment of salt and fluid retention (edema) associated with congestive heart failure.

Guideline-supported / combination use

Xelix SR is commonly used as part of a combination antihypertensive regimen when blood pressure is not adequately controlled with a single agent, and it may be combined with other agents such as ACE inhibitors, angiotensin receptor blockers, or calcium channel blockers under medical supervision.

Indapamide is available as oral tablets, typically as immediate-release tablets (commonly 1.25 mg and 2.5 mg strengths) and, in some markets, as sustained-release tablets (commonly 1.5 mg). Each tablet contains Indapamide as the active pharmaceutical ingredient along with pharmaceutically acceptable excipients. The exact strength and formulation available should be confirmed on the product label.

Xelix SR is a thiazide-like (indoline) diuretic and antihypertensive agent. Although it is often grouped with thiazide diuretics because of a similar mechanism, Xelix SR is chemically distinct, being derived from a sulfonamide with an indoline ring structure. Xelix SR combines mild diuretic activity with a direct vasodilatory effect on vascular smooth muscle, which contributes to its blood-pressure-lowering action even at doses with minimal diuretic effect. Xelix SR is widely used in the long-term management of hypertension and in the treatment of edema associated with congestive heart failure.

Xelix SR belongs to the therapeutic class of thiazide-like diuretics, which are also used as antihypertensive agents. Xelix SR is chemically related to sulfonamide derivatives.

Mechanism of action: Indapamide inhibits sodium reabsorption in the cortical diluting segment of the distal renal tubule by blocking the sodium-chloride symporter, thereby increasing urinary excretion of sodium, chloride, and water, and to a lesser extent, potassium and magnesium. Indapamide also exerts a direct effect on vascular smooth muscle, reducing vascular reactivity to pressor substances such as angiotensin II and norepinephrine, which lowers peripheral vascular resistance and contributes to its antihypertensive effect independent of diuresis at low doses.

Pharmacokinetics: Indapamide is well absorbed after oral administration, is extensively bound to plasma proteins (approximately 71-79%), and is metabolized in the liver. Metabolites and unchanged drug are eliminated mainly via the kidneys and to a lesser extent in the feces. The elimination half-life of Indapamide is approximately 14-18 hours, which supports once-daily dosing.

Xelix SR tablets should be taken by mouth, preferably in the morning, with or without food, and swallowed whole with a glass of water. Sustained-release formulations of Xelix SR should not be crushed, chewed, or split. Taking Xelix SR in the morning helps avoid the need to urinate during the night. Xelix SR should be taken exactly as prescribed by a physician; if a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose, in which case the missed dose should be skipped rather than doubled.

• Lithium: Xelix SR reduces the renal clearance of lithium, increasing the risk of lithium toxicity. This combination should generally be avoided, or lithium levels should be closely monitored if used together.
• Digoxin: Xelix SR-induced hypokalemia can increase the risk of digoxin toxicity, including cardiac arrhythmias. Electrolytes should be monitored closely when Xelix SR is combined with digoxin.
• NSAIDs: Concurrent use with NSAIDs may reduce the diuretic and antihypertensive effect of Xelix SR.
• Other antihypertensive agents: Combining Xelix SR with other blood-pressure-lowering drugs can produce an additive hypotensive effect.
• QT-prolonging drugs: Electrolyte disturbances (hypokalemia, hypomagnesemia) caused by Xelix SR can increase the risk of QT prolongation and arrhythmia when combined with QT-prolonging medications.
• Corticosteroids: Concurrent use with corticosteroids may increase the risk of hypokalemia when combined with Xelix SR.
• Other potassium-wasting diuretics: Combining Xelix SR with other potassium-wasting diuretics increases the risk of additive electrolyte disturbances.

Most adverse effects associated with Xelix SR are mild and transient. Common effects include headache, dizziness, fatigue or weakness, muscle cramps, nervousness, and nausea.

Electrolyte disturbances

Xelix SR can cause hypokalemia, hyponatremia, and hypomagnesemia, especially at higher doses.

Metabolic effects

Xelix SR can raise uric acid levels (risk of gout) and, less commonly than classic thiazides, can raise blood glucose levels.

Other effects

Xelix SR can cause hypotension and increased sensitivity to sunlight (photosensitivity).

Rare but serious effects

Rarely, Xelix SR has been associated with Stevens-Johnson syndrome, acute angle-closure glaucoma, pancreatitis, hepatitis, and blood cell abnormalities. Seek immediate medical attention if any of these occur.

Pregnancy: Xelix SR should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Routine use of diuretics such as Xelix SR in an otherwise healthy pregnant woman is not appropriate, although Xelix SR may be considered when edema results from a pathological cause under medical supervision.

Lactation: It is not well established whether Xelix SR passes into breast milk. Xelix SR may reduce or suppress milk production. If use of Xelix SR is considered essential during breastfeeding, a physician should be consulted, and stopping breastfeeding may be advised.

Serum electrolytes (especially sodium and potassium) and renal function should be monitored periodically during treatment with Xelix SR, particularly in elderly patients, patients with cardiac arrhythmias, and those taking cardiac glycosides such as digoxin.

• Elderly patients, especially elderly women, may be at increased risk of severe hyponatremia with hypokalemia while taking Xelix SR; treatment should start at the lowest effective dose.
• Xelix SR should be used with caution in patients with diabetes, as it may affect blood glucose control.
• Xelix SR should be used with caution in patients with gout or a history of hyperuricemia.
• Rarely, Xelix SR (as a sulfonamide-derived drug) has been associated with acute angle-closure glaucoma; sudden decrease in vision or eye pain requires prompt medical evaluation.
• Xelix SR may increase sensitivity to sunlight; excessive sun exposure should be avoided.
• Xelix SR should be used cautiously in patients with hepatic impairment, since fluid and electrolyte changes can precipitate hepatic coma (see Contraindications for severe hepatic impairment).

Overdose of Xelix SR may cause nausea, vomiting, weakness, gastrointestinal upset, electrolyte imbalance, marked hypotension, and depressed respiration. There is no specific antidote for Xelix SR overdose. If overdose is suspected, seek immediate medical attention or contact a poison control center right away; treatment is supportive, with careful monitoring and correction of fluid and electrolyte status.

Store Xelix SR at room temperature (below 30°C), in a tightly closed, light-resistant container, away from light and moisture. Keep out of reach of children.

Pediatric use

The safety and effectiveness of Xelix SR in pediatric patients have not been established.

Geriatric use

Elderly patients, particularly elderly women, may have an increased risk of severe hyponatremia with hypokalemia while taking Xelix SR; treatment should be started at the lowest recommended dose with close monitoring.

Renal impairment

Xelix SR should be used with caution in mild to moderate renal impairment, with periodic monitoring of renal function and electrolytes; Xelix SR is contraindicated in anuria or severe renal impairment (see Contraindications).

Hepatic impairment

Xelix SR should be used with caution in mild to moderate hepatic impairment, as fluid and electrolyte disturbances can precipitate hepatic coma; Xelix SR is contraindicated in severe hepatic impairment or hepatic encephalopathy (see Contraindications).

Xelix SR is generally used for long-term, chronic management of hypertension, with duration individualized by the treating physician based on blood pressure response and tolerability. For edema associated with congestive heart failure, the duration of Xelix SR therapy depends on the clinical response and underlying condition. Regular medical follow-up is recommended to review the continued need for and dose of Xelix SR.

Indapamide is classified under: thiazide-like diuretics; antihypertensive agents.

Indapamide acts primarily by inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron, which increases sodium and water excretion (diuretic effect). Indapamide also has a direct vasodilatory effect on peripheral blood vessels, reducing peripheral vascular resistance and lowering blood pressure, an effect that is prominent even at low doses with minimal diuretic activity.

C

The safety and effectiveness of Xelix SR in pediatric patients have not been established. Xelix SR is therefore generally not recommended for use in children, and its use in this population should only be considered under specialist medical supervision if no suitable alternative exists.